Toronto centre launches trial testing blood for residual cancer
Princess Margaret Cancer Centre researchers, led by Dr. Lillian Siu, have launched the SHERLOCK trial to enroll 7,000 patients who finished radiation, chemotherapy or other treatments and test their blood for tiny amounts of tumour DNA, known as molecular residual disease. If liquid biopsies are positive, patients could receive additional experimental treatments such as immunotherapies; if negative, further chemo or radiation might be stopped to avoid side effects. The observational trial will follow patients for at least five years, aims to compare results across cancer types, and is funded by a $50-million donation.
The SHERLOCK trial will enroll 7,000 post-treatment cancer patients.
Context
Smaller studies have shown tiny amounts of cancer DNA can appear in blood after treatment. Researchers now need large trials to confirm whether those findings predict recurrence. The SHERLOCK trial will provide longer follow-up and may…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Historical ParallelLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked